|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found that Galectin-9 was strongly upregulated in glioblastoma multiforme compared with normal brain tissues and lower-grade glioma.
|
31609000 |
2020 |
|
Fetal acidosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
T-cell immunoglobulin mucin-3 and galectin-9 levels in peripheral blood mononuclear cells predict fetal acidemia in twin pregnancies.
|
30231785 |
2020 |
|
Endometrial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The Significance of Galectin-1 and Galectin-9 Expression in Endometrial Carcinoma.
|
31487707 |
2020 |
|
Malignant Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Galectin-9, a ligand for T-cell immunoglobulin mucin 3, has shed a new light on the treatment of malignant glioma.
|
31609000 |
2020 |
|
Endometrial adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of Galectin-9 in endometrial adenocarcinoma was significantly different among different historical grades, pathological stages, degrees of myometrial infiltration, and lymph node metastasis (p < 0.05).
|
31487707 |
2020 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found that Galectin-9 was strongly upregulated in glioblastoma multiforme compared with normal brain tissues and lower-grade glioma.
|
31609000 |
2020 |
|
Alzheimer's Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Increased I-BABP and galectin-9 were observed in MCI and AD patients.
|
31593867 |
2019 |
|
Bronchiectasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we identified that serum levels of galectin-9 (Gal-9), a pleiotropic immunomodulatory protein, are elevated in RA patients, and are even further increased in patients with comorbid bronchiectasis, a lung disease caused by chronic inflammation.
|
31430907 |
2019 |
|
Malignant neoplasm of skin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3 and galectin-9 proteins.
|
31354733 |
2019 |
|
Chordoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunopositivity for Gal9 was associated with tumor invasion (p = 0.019), Karnofsky performance status (KPS) score (p = 0.017), and total TIL count (p < 0.001); downregulation of miR-455-5p was correlated with tumor invasion (p = 0.017) and poor prognosis; and the T-cell immunoglobulin and mucin-domain 3 (TIM3)<sup>+</sup> TIL count was associated with chordoma invasion (p = 0.010) and KPS score (p = 0.037).
|
31197461 |
2019 |
|
Cognition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Gal-9 may serve as a novel neuroimmuno-modulatory protein that is involved in driving cognitive deficits in those aging with HIV and may be valuable in tracking cognitive abnormalities.
|
30478799 |
2019 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model.
|
31146370 |
2019 |
|
Exanthema
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema.
|
31034608 |
2019 |
|
Glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients completed general health PROMs (European Quality of Life in 5 Dimensions [EQ-5D] and 36-item Short Form [SF-36]) and PROMs specific to glaucoma (15-item Glaucoma Quality of Life [GQL-15] and 9-item Glaucoma Activity Limitation [GAL-9]) at baseline and exit from the trial.
|
30273622 |
2019 |
|
Herpes NOS
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Whereas the expression of GAL9 and MHC-II was limited, 73% of rhabdomyosarcomas and 100% of osteosarcomas expressed moderate to high levels of Herpes virus entry mediator on the tumor.
|
30870043 |
2019 |
|
Portal Hypertension
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The spleen of cirrhotic patients with PH showed extensive depletion of splenic CD4, CD8, and human leukocyte antigen DR cells along with overexpression of the inhibitory receptors programmed death-1 (PD-1) and T cell immunoglobulin domain and mucin domain-3 and their ligands (PD-L2 and galectin-9).
|
30676849 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The serum level of Gal-9 was significantly increased (P<0.0001) in patients with CLL compared with the control group, and was associated with the clinical stage according to Binet classification, as well as poor cytogenetic and serum CLL prognostic factors.
|
30655861 |
2019 |
|
Lung diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Here, we identified that serum levels of galectin-9 (Gal-9), a pleiotropic immunomodulatory protein, are elevated in RA patients, and are even further increased in patients with comorbid bronchiectasis, a lung disease caused by chronic inflammation.
|
31430907 |
2019 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Galectin-9 is the most potent inducer of cell death in lymphomas and other malignant cell types among the members of the galectin family.
|
30383222 |
2019 |
|
Mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that using an antigalectin 9 mAb with agonistic properties similar to those exerted by galectin-9 may provide a novel multitargeted strategy for the treatment of mesothelioma and possibly other galectin-9 expressing tumors.
|
31413910 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Galectin-9 was expressed on tumor cells in lesional skin of CTCL and the expression levels were associated with decreased CD8<sup>+</sup> T-cell infiltration.
|
31787505 |
2019 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model.
|
31146370 |
2019 |
|
Dermatomyositis, Childhood Type
|
0.010 |
Biomarker
|
disease |
BEFREE |
Galectin-9 and CXCL10 distinguished between active disease and remission in adult patients with DM or NSM (P = 0.0126 for galectin-9 and P < 0.0001 for CXCL10) and were suited for measurement in minimally invasive dried blood spots (healthy controls versus juvenile DM, P = 0.0040 for galectin-9 and P < 0.0001 for CXCL10).
|
30861625 |
2019 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gal-9 may serve as a novel neuroimmuno-modulatory protein that is involved in driving cognitive deficits in those aging with HIV and may be valuable in tracking cognitive abnormalities.
|
30478799 |
2019 |
|
Chronic liver disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Galectin-9 has recently been identified as a potential biomarker in patients with chronic liver disease.
|
31464928 |
2019 |